BioCentury | Jul 27, 2019
Company News

Vitrakvi set to become EU’s first tissue-agnostic cancer drug

...combination with Inlyta axitinib from Pfizer Inc. (NYSE:PFE) for first-line advanced renal cell carcinoma; Lonsurf trifluridine/tipiracil...
...Staff Writer Epidiolex, Epidyolex, cannabidiol Evenity, romosozumab (AMG 785, CDP7851, anti-sclerostin antibody) Inbrija (CVT-301) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Lonsurf, trifluridine/tipiracil (TAS-102) Soliris...
BioCentury | Jul 8, 2019
Clinical News

July 8 Clinical Quick Takes: Hemophilia data from Sangamo-Pfizer, Novo; plus GamaMabs, Xarelto and more

...GamaMabs combo leads to 40% PFS GamaMabs Pharma S.A. (Toulouse, France) said murlentamab plus Lonsurf trifluridine/tipiracil...
...Barcelona. The Taiho subsidiary of Otsuka Holdings Co. Ltd. (Tokyo:4578) and Servier (Neuilly-sur-Seine, France) market Lonsurf...
...receptor type II; TFPI (LACI) - Tissue factor pathway inhibitor Sandi Wong, Staff Writer GM102, 3c23k Lonsurf, trifluridine/tipiracil (TAS-102) PF-07055480...
BioCentury | Mar 1, 2019
Clinical News

FDA approves Lonsurf for gastric cancer

...Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) said FDA approved Lonsurf trifluridine/tipiracil for adult patients with metastatic...
...which Lonsurf prolonged overall survival (OS) compared with placebo in the third-line setting (see "Taiho's Lonsurf...
...Pharmaceutical Co. Ltd., Tokyo, Japan Servier, Neuilly-sur-Seine, France Product: Lonsurf trifluridine/tipiracil Business: Cancer Shannon Lehnbeuter Lonsurf, trifluridine/tipiracil (TAS-102) Otsuka...
BioCentury | May 18, 2018
Clinical News

Taiho's Lonsurf meets OS endpoint in Phase III for gastric cancer

...Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) and partner Servier (Suresnes, France) said Lonsurf trifluridine/tipiracil as third-line...
...June 22, 2015) . Servier, Suresnes, France Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Product: Lonsurf trifluridine/tipiracil...
...status, quality of life (QOL) and safety Status: Phase III data Milestone: NA Sandi Wong Lonsurf, trifluridine/tipiracil (TAS-102) Servier Taiho...
BioCentury | Feb 28, 2018
Distillery Techniques

Disease models

...patients with metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer or metastatic cholangiocarcinoma, responses to Lonsurf trifluridine/tipiracil...
...evaluating how microenvironmental factors affect the organoid responses to treatment. Taiho Pharmaceutical Co. Ltd. markets Lonsurf...
...2017 doi:10.1126/science.aao2774 CONTACT: Nicola Valeri, The Institute of Cancer Research, London, U.K. email: nicola.valeri@icr.ac.uk Jaime De Leon Erbitux Lonsurf regorafenib Stivarga trifluridine/tipiracil Amgen...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Apr 21, 2017
Clinical News

Brontictuzumab: Ph Ib discontinued

...trial in mCRC patients after data showed that third-line treatment with IV brontictuzumab plus Lonsurf trifluridine/tipiracil...
BioCentury | Apr 17, 2017
Clinical News

OncoMed reeling after latest Phase II failure

...grade 3 diarrhea seen in a cohort receiving the lowest dose of brontictuzumab plus Lonsurf trifluridine/tipiracil...
BioCentury | Jan 25, 2017
Clinical News

Brontictuzumab: Ph Ib started

...OncoMed began an open-label, U.S. Phase Ib trial to evaluate brontictuzumab plus Lonsurf trifluridine/tipiracil. A dose-escalation...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
Items per page:
1 - 10 of 45